Pfizer Files More Patent-Infringement Suits on Ibrance Capsules

Pfizer said generic versions of a cancer treatment proposed by Alembic, Cipla, Zydus and Mylan would infringe a patent for its blockbuster Ibrance that expires in February 2034.

• Pfizer is seeking court orders blocking copies until the patent has expired, according to complaints filed Friday in Wilmington, Delaware, and in Newark, New Jersey
• Pfizer also sued Mylan over the same patent on Friday in federal court in Clarksburg, West Virginia
• Patent, titled “Solid Forms of a Selective Cdk4/6 Inhibitor,” was issued in July
  • Pfizer has four other patents on Ibrance that expire in January 2023: FDA Orange Book ...